“Despite the massive improvements in scale-up enabled by single-use bioreactors and a scale-out philosophy, going from process development scale to larger bioreactors remains tricky. That’s especially true when responsibilities are transferred among academic labs, contract development and manufacturing organizations (CDMOs), and biopharma companies, each of which may use different equipment.

Arsenale Bioyards recognized the inefficiencies and developed a platform that could radically change biomanufacturing, much like the Bessemer converter in the mid-19th century transformed the steel industry, making mass production not only possible but also cost-effective.”